SEC Info  
    Home      Search      My Interests      Help      Sign In      Please Sign In

Y-mAbs Therapeutics, Inc. – ‘S-8’ on 3/30/23

On:  Thursday, 3/30/23, at 5:19pm ET   ·   Effective:  3/30/23   ·   Accession #:  1558370-23-5146   ·   File #:  333-271007

Previous ‘S-8’:  ‘S-8’ on 3/22/19   ·   Next & Latest:  ‘S-8’ on 2/29/24   ·   12 References:   

Find Words in Filings emoji
 
  in    Show  and   Hints

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 3/30/23  Y-mAbs Therapeutics, Inc.         S-8         3/30/23    4:168K                                   Toppan Merrill Bridge/FA

Registration Statement – Securities for an Employee Benefit Plan   —   Form S-8   —   SA’33

Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: S-8         Registration Statement - Securities for an          HTML    114K 
                Employee Benefit Plan                                            
 2: EX-5.1      Opinion of Counsel re: Legality                     HTML     18K 
 3: EX-23.1     Consent of Expert or Counsel                        HTML      5K 
 4: EX-FILING FEES  Filing Fees                                     HTML     28K 


‘S-8’   —   Registration Statement – Securities for an Employee Benefit Plan

Document Table of Contents

Page (sequential)   (alphabetic) Top
 
11st Page  –  Filing Submission
"Power of Attorney (included on the signature page of this Form S-8)

This is an HTML Document rendered as filed.  [ Alternative Formats ]



 C:  <!  <> 

As filed with the Securities and Exchange Commission on March 30, 2023

Registration No. 333-

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549


FORM S-8

REGISTRATION STATEMENT

UNDER

THE SECURITIES ACT OF 1933


Y-mAbs Therapeutics, Inc.

(Exact name of Registrant as specified in its charter)

Delaware

    

47-4619612

(State or other jurisdiction of incorporation or organization)

(I.R.S. Employer Identification No.)

230 Park Avenue Suite 3350

New York, NY 10169

(Address of principal executive offices) (Zip code)


2018 Equity Incentive Plan

(Full title of the plans)


Thomas Gad

Founder, President, Interim Chief Executive Officer and

Head of Business Development and Strategy

Y-mAbs Therapeutics, Inc.

230 Park Avenue, 33rd Floor

New York, New York 10169

Tel: (646) 885-8505

(Name, address, including zip code, and telephone number, including area code, of agent for service)

Copies to:

Divakar Gupta

Sarah K. Sellers

Cooley LLP

55 Hudson Yards

New York, NY 10001

Telephone: (212) 479-6000

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer

Accelerated filer

Non-accelerated filer

Smaller reporting company

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act.


EXPLANATORY NOTE

Y-mAbs Therapeutics, Inc. (the “Registrant”) is filing this Registration Statement on Form S-8 with the Securities and Exchange Commission (the “Commission”) for the purpose of registering 8,078,887 shares of the Registrant’s common stock, par value $0.0001 per share (the “Common Stock”), issuable to eligible persons under the Registrant’s 2018 Equity Incentive Plan (the “2018 EIP”), which Common Stock is in addition to, and of the same class as, the shares of Common Stock for which an original registration statement on Form S-8 (File No. 333-230455) was filed with the Commission on March 22, 2019 (the “Original S-8 Registration Statement”). Accordingly, the contents of the Original Registration Statement are incorporated by reference into this Registration Statement pursuant to General Instruction E of Form S-8. The additional shares of Common Stock registered hereby have become reserved for issuance as a result of the operation of the “evergreen” provision in the 2018 EIP, which provides that the total number of shares subject to the plan may be increased each year pursuant to a specified formula as set forth in the 2018 EIP.


PART II

ITEM 3. INCORPORATION OF DOCUMENTS BY REFERENCE

The following documents filed by the Registrant with the Commission are incorporated by reference into this Registration Statement:

The Registrant’s Annual Report on Form 10-K for the year ended December 31, 2022, filed with the Commission on March 30, 2023.

The description of the Registrant’s Common Stock which is contained in a registration statement on Form 8-A filed on September 11, 2018 (File No. 001-38650) under the Exchange Act of 1934, as amended (the “Exchange Act”), including any amendment or report filed for the purpose of updating such description.

The contents of the Registrant’s  Registration Statement on Form S-8 filed with the Commission on March 22, 2019 (File No. 333-230455), pursuant to which the Registrant previously registered shares of its Common Stock for issuance under the 2018 EIP.

The Registrant’s Current Reports on Form 8-K filed with the Commission on January 4, 2023 (with respect to Item 2.05 only), February 2, 2023 and March 13, 2023.

All other reports and documents subsequently filed by the Registrant pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act (other than Current Reports furnished under Item 2.02 or Item 7.01 of Form 8-K and exhibits furnished on such form that relate to such items) on or after the date of this Registration Statement and prior to the filing of a post-effective amendment to this Registration Statement which indicates that all securities offered have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference herein and to be a part of this Registration Statement from the date of the filing of such reports and documents. Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein or in any subsequently filed document that also is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.


EXHIBITS

ITEM 8.

    

    

Incorporated by Reference

 

Exhibit
Number

Description

Schedule
Form

    

File Number

    

Exhibit

    

Filing Date

4.1

Amended and Restated Certificate of Incorporation.

8-K

001-38650

3.1

September 26, 2018

4.2

Amended and Restated Bylaws.

8-K

001-38650

3.2

September 26, 2018

4.3

Specimen stock certificate evidencing the shares of Common Stock.

S-1

333-226999

4.1

August 24, 2018

99.1

2018 Equity Incentive Plan

S-1

333-226999

10.9

August 24, 2018

99.2

Form of Stock Option Grant Notice and Stock Option Agreement under the 2018 Equity Incentive Plan (as amended, employees, consultants and service providers other than directors).

10-Q

001-38650

10.8

November 5, 2020

99.3

Form of Stock Option Grant Notice and Stock Option Agreement under the 2018 Equity Incentive Plan (as amended, directors).

10-Q

001-38650

10.9

November 5, 2020

99.4

Form of Stock Option Grant Notice and Stock Option Agreement under the 2018 Equity Incentive Plan.

10-Q

001-38650

10.1

November 7, 2022

99.5

Form of Stock Option Grant Notice and Stock Option Agreement for directors under the 2018 Equity Incentive Plan.

10-Q

001-38650

10.2

November 7, 2022

99.6

Form of Restricted Stock Award Grant Notice and Restricted Stock Award Agreement under the 2018 Equity Incentive Plan.

S-1

333-226999

10.16

August 24, 2018

99.7

Form of Restricted Stock Unit Award Grant Notice and Restricted Stock Unit Award Agreement under the 2018 Equity Incentive Plan.

S-1

333-226999

10.17

August 24, 2018

5.1*

Opinion of Cooley LLP.

23.1*

Consent of PricewaterhouseCoopers LLP, Independent Registered Public Accounting Firm.

23.2*

Consent of Cooley LLP (included in Exhibit 5.1).

24.1*

Power of Attorney (included on the signature page of this Form S-8)

107*

Exhibit Fee Table


*

Filed herewith.


SIGNATURES

Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement or amendment thereto to be signed on its behalf by the undersigned, thereunto duly authorized, in New York City, State of New York, on this 30th day of March 2023.

Y-MABS THERAPEUTICS, INC.

By:

/s/ THOMAS GAD

Name: Thomas Gad

Title: Founder, President, Interim Chief Executive Officer, and

Head of Business Development & Strategy


POWER OF ATTORNEY

KNOW ALL BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints Thomas Gad, Bo Kruse and Sune Reinholth Nyland, and each of them, as his or her true and lawful attorneys-in-fact and agents, each with the full power of substitution, for him or her and in his or her name, place or stead, in any and all capacities, to sign any and all amendments to this Registration Statement (including post-effective amendments), and to file the same, with exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or their substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.

Name

    

Position

    

Date

/s/ THOMAS GAD

Founder, President, Interim Chief Executive
Officer and Head of Business Development and Strategy
(Principal Executive Officer)

March 30, 2023

Thomas Gad

/s/ BO KRUSE

EVP, Chief Financial Officer
(Principal Financial Officer and Principal
Accounting Officer)

March 30, 2023

Bo Kruse

/s/ JOHAN WEDELL-WEDELLSBORG

Director

March 30, 2023

Johan Wedell-Wedellsborg

/s/ LAURA J. HAMILL

Director

March 30, 2023

Laura J. Hamill

/s/ GÉRARD BER

Director

March 30, 2023

Gérard Ber

/s/ ASHUTOSH TYAGI

Director

March 30, 2023

Ashutosh Tyagi

/s/ JAMES I. HEALEY

Director

March 30, 2023

James I. Healy

/s/ DAVID N. GILL

Director

March 30, 2023

David N. Gill




Dates Referenced Herein   and   Documents Incorporated by Reference

This ‘S-8’ Filing    Date    Other Filings
Filed on / Effective on:3/30/2310-K,  8-K,  S-3
12/31/2210-K
11/7/2210-Q,  8-K
11/5/2010-Q,  4,  8-K
3/22/1910-K,  8-K,  S-8
9/26/184,  8-K
8/24/18DRS,  DRS/A,  S-1
 List all Filings 


1 Subsequent Filing that References this Filing

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 2/29/24  Y-mAbs Therapeutics, Inc.         S-8         2/29/24    4:185K                                   Toppan Merrill Bridge/FA


11 Previous Filings that this Filing References

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 3/30/23  Y-mAbs Therapeutics, Inc.         10-K       12/31/22  106:10M                                    Toppan Merrill Bridge/FA
 3/13/23  Y-mAbs Therapeutics, Inc.         8-K:8       3/13/23   10:183K                                   Toppan Merrill/FA
 2/02/23  Y-mAbs Therapeutics, Inc.         8-K:8,9     2/02/23   11:209K                                   Toppan Merrill/FA
 1/04/23  Y-mAbs Therapeutics, Inc.         8-K:2,7,9   1/03/23   11:249K                                   Toppan Merrill/FA
11/07/22  Y-mAbs Therapeutics, Inc.         10-Q        9/30/22   88:8.4M                                   Toppan Merrill Bridge/FA
11/05/20  Y-mAbs Therapeutics, Inc.         10-Q        9/30/20   68:6.7M                                   Toppan Merrill Bridge/FA
 3/22/19  Y-mAbs Therapeutics, Inc.         S-8         3/22/19    3:227K                                   Toppan Merrill/FA
 9/26/18  Y-mAbs Therapeutics, Inc.         8-K:5,7,9   9/25/18    4:284K                                   Toppan Merrill/FA
 9/11/18  Y-mAbs Therapeutics, Inc.         8-A12B                 1:23K                                    Toppan Merrill/FA
 9/07/18  Y-mAbs Therapeutics, Inc.         S-1/A                  5:4.4M                                   Toppan Merrill-FA
 8/24/18  Y-mAbs Therapeutics, Inc.         S-1                   31:12M                                    Toppan Merrill-FA
Top
Filing Submission 0001558370-23-005146   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)

Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
AboutPrivacyRedactionsHelp — Thu., May 16, 10:07:54.2am ET